PCS
PMVP icon

Personal CFO Solutions’s PMV Pharmaceuticals PMVP Stock Holding History

Personal CFO Solutions’s Portfolio PMVP Stock Details PMVP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-550,342
Closed -$820K – 575
2024
Q3 		$820K Hold
550,342
– – 0.11% 184
2024
Q2 		$892K Hold
550,342
– – 0.14% 141
2024
Q1 		$936K Hold
550,342
– – 0.15% 138
2023
Q4 		$1.71M Buy
550,342
+200,000
+57% +$529K 0.3% 64
2023
Q3 		$2.15M Hold
350,342
– – 0.43% 51
2023
Q2 		$2.19M Sell
350,342
-200,000
-36% -$1.05M 0.45% 50
2023
Q1 		$2.63M Hold
550,342
– – 0.54% 38
2022
Q4 		$4.79M Hold
550,342
– – 1.01% 19
2022
Q3 		$6.55M Hold
550,342
– – 1.64% 11
2022
Q2 		$7.84M Buy
550,342
+200,000
+57% +$2.91M 1.84% 9
2022
Q1 		$7.29M Sell
350,342
-200,000
-36% -$3.53M 1.44% 13
2021
Q4 		$12.7M Buy
550,342
+195,000
+55% +$4.71M 2.38% 7
2021
Q3 		$10.6M Sell
355,342
-30,000
-8% -$958K 2.17% 8
2021
Q2 		$13.2M Sell
385,342
-469,342
-55% -$15.7M 2.7% 6
2021
Q1 		$28.1M Buy
+854,684
New +$33.7M 6.08% 1

Other funds holding PMVP

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Personal CFO Solutions's PMVP Position: Q4 2024 in Review

Personal CFO Solutions sold out of PMV Pharmaceuticals (PMVP) in Q4 2024, closing a stake of 550,342 shares — an estimated $820K sold.

Personal CFO Solutions first reported a position in PMVP in Q1 2021 and held it in 15 quarters. The position peaked at $28.1M in Q1 2021. 70 funds tracked by Wall St. Rank hold PMVP as of Q4 2024.

  • Personal CFO Solutions reported no remaining PMV Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Personal CFO Solutions sold 550,342 PMV Pharmaceuticals shares in Q4 2024, an estimated $820K.
  • Personal CFO Solutions first reported a position in PMV Pharmaceuticals in Q1 2021 and held it in 15 quarters.
  • Personal CFO Solutions's PMV Pharmaceuticals position peaked at $28.1M in Q1 2021.
  • 70 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q4 2024.

Based on Personal CFO Solutions's 13F filing for Q4 2024, filed 7 Feb 2025.